Global Cancer Biomarkers Market Size, Share, Growth Analysis, By Profiling Technology, By Biomolecules, By Cancer, By Application

Description

Global Cancer Biomarkers Market size was valued at USD 13.24 Billion in 2022 and is poised to grow from USD 14.83 Billion in 2023 to USD 29.49 Billion by 2031, growing at a CAGR of 13.6% in the forecast period (2024-2031)

The anticipated expansion of the worldwide market for cancer biomarkers is indicative of a significant increase in the incidence of many cancer kinds, including lung, prostate, and breast cancer. The increase in cancer cases is what will fuel the market's growth during the projection period.

Furthermore, the need for efficient biomarkers is fueled by the growing importance of targeted and biological therapies in the treatment of cancer. This rising trajectory is further supported by technological improvements that improve the precision and consistency of cancer biomarkers, which in turn improves treatment monitoring and diagnostic capacities.

Global Cancer Biomarkers Market Segmental Analysis

Five segments comprise the global market for cancer biomarkers: profiling technique, cancer type, biomolecule, application, and geography. The market is divided into four segments based on profiling technology: cytogenetics-based tests, immunoassays, imaging technologies, and omic technologies. The market is divided into four segments based on biomolecules: genetic, protein, glyco-, and epigenetic biomarkers. The market is divided into categories according to the kind of cancer: breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, and others. The market is divided into five segments based on application: risk assessment, prognostics, drug discovery and development, diagnostics, and others. The market is divided into the following regions: Asia-Pacific, Japan, China, India, South Korea, Australia, Rest of Asia-Pacific, LAMEA, Brazil, Saudi Arabia, Rest of Europe, North America, U.S., Canada, Mexico, Europe, Germany, UK, Italy, France, Spain, and Rest of LAMEA.

Drivers of the Global Biobanking Market

Many pharmaceutical companies are investing heavily in cutting-edge research and development projects centered on new biomarkers designed for cancer detection and therapy. A number of intriguing prospects are almost finished with their development stages and should advance significantly when they debut. These possible biomarkers have the capacity to completely transform the way that cancer is diagnosed and treated by providing increased precision and effectiveness.

Restraints in the Global Cancer Biomarkers Market

A major barrier in the cancer biomarker industry contrasts with the rising global prevalence of cancer and the growing need for diagnostic tools. the lack of comprehensive biomarker test reimbursement rules in both established and emerging countries. This deficiency limits the global demand for biomarkers by impeding the widespread adoption of these essential diagnostic tools. Another significant obstacle is the high expense of cancer detection and treatment, which is particularly common in developing nations.

Market Trends of the Global Cancer Biomarkers Market

The market for cancer biomarkers is expected to grow significantly over the next ten years due to a number of important elements coming together. Growing patient and healthcare professional knowledge of the need of early detection in treating malignancies is a key factor in this growth. This increased consciousness encourages early diagnosis in a proactive manner, resulting in prompt treatments that may lead to better treatment outcomes.

Product Code: SQMIG35A2622

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Cancer Biomarkers Market by Profiling Technology

Market Overview
Omic Technologies
Imaging Technologies
Immunoassays
and Cytogenetics-based Tests

Global Cancer Biomarkers Market by Biomolecules

Market Overview
Genetic Biomarkers
Protein Biomarkers
Epigenetics
and Glyco-biomarkers

Global Cancer Biomarkers Market by Cancer

Market Overview
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
and Others

Global Cancer Biomarkers Market by Application

Market Overview
Diagnostics
Drug Discovery and Development
Prognostics
Risk Assessment
and Others

Global Cancer Biomarkers Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

F. Hoffmann-LA Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

Global Cancer Biomarkers Market Size, Share, Growth Analysis, By Profiling Technology, By Biomolecules, By Cancer, By Application - Industry Forecast 2023-2030